Pharmaceutical Technology17m
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Pharmaceutical Technology23m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology19m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Eloralintide?
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
Pharmaceutical Technology23m
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Pharmaceutical Technology26m
Risk adjusted net present value: What is the current valuation of Sanofi’s Duvakitug?
Duvakitug is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Ulcerative Colitis;Crohn's Disease (Regional Enteritis).
Pharmaceutical Technology24m
Risk adjusted net present value: What is the current valuation of Keros Therapeutics’s Cibotercept?
Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.
Pharmaceutical Technology41m
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.
Pharmaceutical Technology50m
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies’s ITI-333?
ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.
Pharmaceutical Technology44m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.